000282509 001__ 282509
000282509 005__ 20240918104004.0
000282509 0247_ $$2doi$$a10.1007/s00120-023-02190-6
000282509 0247_ $$2pmid$$apmid:37666944
000282509 0247_ $$2ISSN$$a2731-7064
000282509 0247_ $$2ISSN$$a0042-1103
000282509 0247_ $$2ISSN$$a0340-2592
000282509 0247_ $$2ISSN$$a1433-0563
000282509 0247_ $$2ISSN$$a2731-7072
000282509 037__ $$aDKFZ-2023-01798
000282509 041__ $$aGerman
000282509 082__ $$a610
000282509 1001_ $$aHandke, Analena Elisa$$b0
000282509 245__ $$aProstate cancer-multiparametric MRI and alternative approaches in intervention and therapy planning.[Multiparametrische MRT und alternative Methoden in der Interventions- und Behandlungsplanung beim Prostatakarzinom].
000282509 260__ $$aNew York]$$bSpringer Medizin$$c2023
000282509 3367_ $$2DRIVER$$aarticle
000282509 3367_ $$2DataCite$$aOutput Types/Journal article
000282509 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1726648779_11602$$xReview Article
000282509 3367_ $$2BibTeX$$aARTICLE
000282509 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000282509 3367_ $$00$$2EndNote$$aJournal Article
000282509 500__ $$a2023 Nov;62(11):1160-1168
000282509 520__ $$aIn recent years, multiparametric magnetic resonance imaging (mpMRI) of the prostate has gained importance and plays a crucial role in both personalized diagnostics and increasingly in the treatment planning for patients with prostate cancer.The aim of this study is to present established and innovative applications of MRI in the diagnosis and treatment of localized prostate cancer, evaluating their strengths and weaknesses. Furthermore, it will explore alternative approaches and compare them in a comprehensive manner.A systematic literature review on the application of mpMRI for biopsy and therapy planning was conducted.The integration of modern imaging techniques, especially mpMRI, into the diagnostic algorithm has revolutionized prostate cancer diagnosis. MRI and MRI-guided biopsy detect more significant prostate cancer, with the potential to reduce unnecessary biopsies and the diagnosis of clinically insignificant carcinomas. In addition, MRI provides crucial information for risk stratification and treatment planning in prostate cancer patients, both before radical prostatectomy and during active surveillance.Multiparametric MRI offers significant added value for the diagnosis and treatment of localized prostate cancer. The advancement of MRI analysis, such as the implementation of artificial intelligence algorithms, holds the potential for further enhancing imaging diagnostics.
000282509 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000282509 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000282509 650_7 $$2Other$$aActive surveillance
000282509 650_7 $$2Other$$aBiopsy
000282509 650_7 $$2Other$$aQuality assurance
000282509 650_7 $$2Other$$aRisk stratification
000282509 650_7 $$2Other$$aUltrasonography
000282509 7001_ $$aRitter, Manuel$$b1
000282509 7001_ $$0P:(DE-He78)f84639cbc39bc20ecda8d00e6de97578$$aAlbers, Peter$$b2$$udkfz
000282509 7001_ $$aNoldus, Joachim$$b3
000282509 7001_ $$0P:(DE-He78)79897f8897ff77676549d9895258a0f2$$aRadtke, Jan Philipp$$b4$$udkfz
000282509 7001_ $$aKrausewitz, Philipp$$b5
000282509 773__ $$0PERI:(DE-600)3123197-4$$a10.1007/s00120-023-02190-6$$n11$$p1160-1168$$tDie Urologie$$v62$$x2731-7064$$y2023
000282509 909CO $$ooai:inrepo02.dkfz.de:282509$$pVDB
000282509 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f84639cbc39bc20ecda8d00e6de97578$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000282509 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)79897f8897ff77676549d9895258a0f2$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000282509 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000282509 9141_ $$y2023
000282509 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2022-11-08$$wger
000282509 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2022-11-08$$wger
000282509 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-08
000282509 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-08
000282509 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-08
000282509 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-22
000282509 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-22
000282509 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-22
000282509 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-22
000282509 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-22
000282509 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-22
000282509 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bUROLOGIE : 2022$$d2023-08-22
000282509 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-22
000282509 9201_ $$0I:(DE-He78)C130-20160331$$kC130$$lPersonalisierte Früherkennung des Prostatakarzinoms$$x0
000282509 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lE010 Radiologie$$x1
000282509 980__ $$ajournal
000282509 980__ $$aVDB
000282509 980__ $$aI:(DE-He78)C130-20160331
000282509 980__ $$aI:(DE-He78)E010-20160331
000282509 980__ $$aUNRESTRICTED